Semaglutide produces approximately 15% weight loss, tirzepatide achieves around 21%, and Retatrutide delivers over 24% in clinical trials
1 Mechanism of total glutathione quantification Fig
Key Takeaways GLP-1 patches are not supported by the same level of evidence as prescription GLP-1 medicines
In December 2025, the CagriSema dossier for weight management was submitted to the US FDA on the basis of the REDEFINE 1 and REDEFINE 2 studies
Sin embargo, no todos los estudios en este campo son concluyentes y, aunque muestran un beneficio posible, no son significativos desde el punto de vista estadstico
Semaglutide can be a short-term tool or part of a longer-term strategy, the key is using it thoughtfully and with a plan for what comes next